Study 8 of 46 for search of: "Lymphedema"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors
This study has been completed.
Sponsored by: National Center for Complementary and Alternative Medicine (NCCAM)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier: NCT00064857
  Purpose

The goal of this study is to evaluate the effectiveness of a standardized botanical extract of Pycnogenol as a treatment for stable arm lymphedema in breast cancer survivors.


Condition Intervention Phase
Lymphedema
Breast
Cancer
Drug: Pycnogenol
Phase II

Genetics Home Reference related topics: breast cancer lymphedema-distichiasis syndrome
MedlinePlus related topics: Breast Cancer Cancer Lymphedema
Drug Information available for: Pycnogenol
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment: 26
Study Start Date: August 2003
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Lymphedema of the arm affects the function and self-image of approximately 600,000 of the 2 million breast cancer survivors in the United States. Chronic lymphedema can lead to recurrent infections and permanent swelling, in some cases impairing function. Although various methods of massage and the use of non-elastic compression "sleeves" have been shown to decrease the severity of lymphedema, these methods of physical therapy are limited in terms of patient acceptance, compliance, and by the availability of trained therapists. There is presently no pharmacologic treatment that has proven effective in treating or preventing the development of lymphedema in women treated for breast cancer. This is a double-blind, placebo-controlled trial of an extract of the bark of the French maritime pine tree (Pycnogenol(r)) as a treatment for arm lymphedema in breast cancer survivors. Pycnogenol(r) is widely used in Europe for lymphedema of the leg and varicose veins, and is thought to act by several mechanisms including vascular permeability and vascular constriction. The development of such a therapeutic approach would therefore constitute a major breakthrough in the treatment of this common symptom of breast cancer lymphedema. Bioelectric impedance is a painless, quick, and easily-performed method of estimating the extracellular and total water volume of the body or segment, such as the arm. We will compare the correlation of both a single- and a multiple-frequency bioelectric impedance instrument in measuring change in arm volume to a standard assessment using water displacement. We expect that bioelectric impedance will prove faster and more sensitive to changes in extracellular water (lymphedema) than the water displacement method. We also propose to use a small oral dose of midazolam and single blood sampling to screen for effects of Pycnogenol(r) on the activity of the common drug metabolizing enzyme CYP3A4. For those subjects who are already receiving digoxin, we will use digoxin urine excretion to screen for effects of the botanical upon the activity of P-glycoprotein. Finally, we will continue the evaluation of a new questionnaire of lymphedema symptoms presently being tested as a tool for assessing the severity and improvement of symptoms with treatment. In summary, the successful completion of this research can be expected to provide an alternative therapy and new instruments for treating and measuring lymphedema.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Unilateral (ipsilateral to breast cancer resection side) lymphedema of the upper extremity.
  • Extravascular water ration of > 1.07/1 between affected vs. normal arm using multiple frequency bioelectric impedence
  • Patient is > 2months from last surgical or radiation treatment to the affected axilla
  • Renal and hepatic function:

Creatinine clearance > 50ml/min, total bili <2 mg/dl, transaminases <1.5 x ULN

  • Patient not pregnant or breastfeeding. Use of barrier contraception if sexually active.
  • ECOG performance of 0-2
  • Patient not allergic to pycnogenol

Exclusion criteria:

  • Patients treated with their first course of chemotherapy or radiation
  • Chemotherapy or radiation to axillary lymph node will exclude patients for 8 weeks following treatment
  • Patients with more than one episode of arm cellulitis, venous clot, or woody fibrosis of the affected arm. Antibiotics used to treat cellulitis must be completed at least 4 weeks prior to initial screening
  • Patients with a defibrillator Midazolam study only: Patients requiring or benefiting from supplemental oxygen, patients allergic to cherries
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00064857

Locations
United States, Wisconsin
University of Wisconsin Comprehensive Cancer Center and School of Pharmacy
Madison, Wisconsin, United States, 53706
Sponsors and Collaborators
Investigators
Study Chair: James F. Cleary, M.B.B.S. University of Wisconsin, Madison
  More Information

Study ID Numbers: R21 AT001724-01
Study First Received: July 14, 2003
Last Updated: April 21, 2008
ClinicalTrials.gov Identifier: NCT00064857  
Health Authority: United States: Federal Government;   United States: Food and Drug Administration

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
lymphedema
breast
cancer
plant preparation
herbal preparation
pine bark extract

Study placed in the following topic categories:
Lymphedema
Lymphatic Diseases
Skin Diseases
Pycnogenols
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Immunologic Factors
Therapeutic Uses
Hematologic Agents
Physiological Effects of Drugs
Adjuvants, Immunologic
Platelet Aggregation Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009